Sa2072 Simeprevir (TMC435) With Peginterferon/Ribavirin for Chronic HCV Genotype-1 Infection in Treatment-Nai;auve Patients: Results From QUEST-1, a Phase III Trial

Gastroenterology(2013)

Cited 3|Views8
No score
Abstract
IAP may represent a novel therapeutic strategy to prevent fructose-induced obesity and diabetes.The beneficial effects of IAP may derive from the preservation of normal flora homeostasis and gut epithelial barrier function.
More
Translated text
Key words
peginterferon/ribavirin,infection,peginterferon/ribavirin,treatment-nai
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined